story of the week
Ipatasertib Plus Paclitaxel vs Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ipatasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Lancet Oncol 2017 Aug 08;[EPub Ahead of Print], SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, C Saura, MJ Wongchenko, AV Kapp, WY Chan, SM Singel, DJ Maslyar, J BaselgaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.